Mississauga, Ont.-based BioSyent Inc. says on Monday it has entered into a share purchase agreement to acquire Oral Science Inc., a privately owned Canadian distributor of dental hygiene and oral health products, in a deal valued at $25.5 million.
The agreement, dated Feb. 8, will see BioSyent acquire 100 per cent of the issued and outstanding shares of Oral Science in an arm’s-length transaction. Oral Science is based in Brossard, Que.
“We are excited to announce our acquisition of Oral Science, which provides BioSyent with a new platform for portfolio expansion and revenue and profit growth,” said René Goehrum, president and CEO of BioSyent. “Oral Science is a Canadian success story much like our own.”
BioSyent markets and distributes a range of healthcare products, including over-the-counter, behind-the-counter and prescription medicines.
The purchase price includes $22.5 million in cash and 234,192 BioSyent common shares valued at $12.81 per share, representing $3.0 million in aggregate. The price includes a $6.3-million net working capital requirement at closing.
The sellers are also eligible for a contingent cash earn-out in 2027 based on Oral Science’s performance in 2025 and 2026, as well as contingent royalty payments tied to future sales of one product through 2033, capped at $6.0 million.
Related: Patterson shareholders approve $4.1B acquisition, nearing private company status
Related: Dentalcorp securityholders approve acquisition by GTCR-affiliated funds
‘Milestone ensures sustainability’
“On behalf of the owners and leadership team of Oral Science, I am very pleased to enter into this agreement with BioSyent,” said Daniel Ménard, co-founder and president of Oral Science. “This milestone ensures the long-term sustainability of Oral Science.”
Subject to customary closing conditions and required regulatory approvals, the transaction is expected to close before the end of February 2026. No finder’s fees are payable.
Founded in 2003, Oral Science partners with dental practices to support care in periodontal and endodontic disease, high-risk caries, dry mouth and oral lesions. Fifty-four per cent of its revenue comes from sales to dental clinics, with the remainder generated through retail pharmacy and direct-to-consumer online sales.
Following closing, Oral Science will continue to operate from its Brossard head office as a standalone business unit within BioSyent. Its founders and leadership team will remain in place and will become shareholders of BioSyent as part of the transaction.
BioSyent said it plans to continue investing in new pharmaceutical and oral health products to support growth across both businesses.